56136-82-4

Basic information

• Product Name: BUTTPARK 45\01-52
• Synonyms: BUTTPARK 45\01-52
• CAS NO: 56136-82-4
• Molecular Formula: C₈H₉BrN₂O₂
• Molecular Weight: 245.075
• Mol File: 56136-82-4.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: BUTTPARK 45\01-52(CAS DataBase Reference)
• NIST Chemistry Reference: BUTTPARK 45\01-52(56136-82-4)
• EPA Substance Registry System: BUTTPARK 45\01-52(56136-82-4)

Safety Data

• Hazardous Substances Data: 56136-82-4(Hazardous Substances Data)

Usage

General Description

The term "BUTTPARK 45\01-52" does not refer to any classified or recognized chemical compound or substance. It seems like it could be a code, model number, or placeholder, but without further context or information, it's difficult to provide a concrete description or summary. Please cross-verify and ensure that the term is accurate and related to the chemical field.

Upstream product

• 364-73-8 4-Bromo-1-fluoro-2-nitrobenzene 
• 557-66-4 ethanamine hydrochloride 
• 3460-18-2 1,4-dibromo-2-nitrobenzene 
• 109-89-7 diethylamine 
• 75-04-7 ethylamine 

Downstream Products

• 23073-51-0 5-bromo-1-ethyl-1H-benzimidazole 

Relevant articles and documents

INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES

Provided herein are heteroaryl inhibitors of fibroblast growth factor receptor kinases, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.

Compound Shape Effects in Minor Groove Binding Affinity and Specificity for Mixed Sequence DNA

AT specific heterocyclic cations that bind in the DNA duplex minor groove have had major successes as cell and nuclear stains and as therapeutic agents which can effectively enter human cells. Expanding the DNA sequence recognition capability of the minor

Condensed derivatives of imidazole useful as pharmaceuticals

The invention relates to the compounds (I) and their acids and bases salts: wherein: the dotted line indicates a double bond; X is N or C-R1 and Y is N or C-R2, X and Y not being simultaneously N; A is selected from the group consisting of phenyl, naphthyl and (5-11) membered monocyclic or bicyclic unsaturated cycle or heterocycle possibly substituted as defined in the application, and A can also comprise either a further (4-7) membered heterocycle, said heterocycle being a monocycle, fused, saturated or unsaturated, the polycyclic system then comprising up to 14 members and up to 5 heteroatoms selected from N, O and S; B is Hydrogen or a substituent as defined in the application, or B is a (4-10) membered mono or bicyclic saturated or unsaturated heterocycle containing 1-3 heteroatoms selected from N, O and S, and possibly substituted as defined in the application; B not being Hydrogen when X is N and Y is C-R2; R1 is Hydrogen or a substituent as defined in the application; B and R1 cannot be simultaneously Hydrogen; R2 is Hydrogen or Halogen; their preparation, their use in the antibacterial prevention and therapy, alone or in association with antibacterials, antivirulence agents or drugs reinforcing the host innate immunity, and pharmaceutical compositions and associations containing them.